Skip to main content
SpringerLink
Log in

Schwerpunkt "Akute myeloische Leukämie"

Erstlinientherapie intensiv-therapierbarer AML-Patient*innen

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© Franziska Modemann /UKE

2

Literatur

  1. Oken MMet al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55

  2. Röllig CB et al. Onkopedia-Leitlinie Akute Myeloische Leukämie (AML). https://www.onkopedia.com/de/onkopedia/guidelines/akute-myeloische-leukaemie-aml/@@guideline/html/index.html abgerufen 1. Juli 2022

  3. Sorror ML et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9

  4. Kantarjian H et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090-8

  5. Röllig C et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020;136(7):823-30

  6. Rowe JM. The "7 + 3" regimen in acute myeloid leukemia. Haematologica. 2022;107(1):3

  7. Agency EM. Rydapt 2022; https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt (abgerufen 1. Juli 2022)

  8. Agency EM. Vyxeos liposomal (previously known as Vyxeos) 2020; https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal abgerufen 1. Juli 2022

  9. Agency EM. Mylotarg 2018; https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0 abgerufen 1. Juli 2022

  10. Ageny EM. Venclyxto 2021; https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto abgerufen 1. Juli 2022

  11. Agency EM. Daurismo 2020; https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo#product-information-section abgerufen 1. Juli 2022

  12. Agency EM. Onureg 2021 https://www.ema.europa.eu/en/medicines/human/EPAR/onureg abgerufen 1. Juli 2022

  13. Lancet JE et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684-92

  14. Benitez LL et al. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma. 2021;62(9):2184-92

  15. Chiche E et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5(1):176-84

  16. Dohner H et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47

  17. Lambert J et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104(1):113-9

  18. Hills RK et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986-96

  19. Stone RM et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-64

  20. Schlenk RF et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840-51

  21. Sharvit G et al. Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy. Clin Lymphoma Myeloma Leuk. 2022;22(2):e116-e23

  22. Röllig C et al. Remission and Survival after Single Versus Double Induction with 7 + 3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial. Blood. 2020;136(Suppl 1):Abstr 458

  23. Magina KN et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130(7):946-8

  24. Döhner H et al. Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance. Blood. 2021;138(Suppl 1):Abstr 804

  25. Bataller A et al. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol. 2020;191(1):52-61

  26. Burchert Aet al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993-3002

  27. Larson RA et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021;35(9):2539-51

  28. Döhner H et al. Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine for patients with acute myeloid leukemia in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis 2021; https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324539 abgerufen 1. Juli 2022

  29. Wei AH et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med. 2020;383(26):2526-37

  30. Heuser M et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753-67

Download references

Author information

Authors and Affiliations

  1. II. Medizinische Klinik, Abteilung für Onkologie, Hämatologie und Knochenmarktransplantation mit Division Pneumologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    Franziska Modemann &  Susanne Ghandili

  2. Univ.-Klinikum Hamburg-Eppendorf, Klinik f. Onkol., Hämatol. u. Stammzellentransplantation, Martinistr. 52, 22046, Hamburg, Deutschland

    Carsten Bokemeyer

  3. II. Medizinische Klinik und Poliklinik für Onkologie, Hämatologie und Knochenmarktransplantation mit der Sektion Pneumologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Deutschland

    Walter Fiedler

Authors
  1. Franziska Modemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Ghandili
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carsten Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter Fiedler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Modemann, F., Ghandili, S., Bokemeyer, C. et al. Erstlinientherapie intensiv-therapierbarer AML-Patient*innen. InFo Hämatol Onkol 25, 16–21 (2022). https://doi.org/10.1007/s15004-022-9123-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-022-9123-2

Search

Navigation